CNS Pharmaceuticals
CNSP
11 hedge funds and large institutions have $1.34M invested in CNS Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 5 closing their positions.
284% more capital invested
Capital invested by funds: $349K → $1.34M (+$992K)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
4.29% less ownership
Funds ownership: 23.47% → 19.19% (-4.3%)
8% less funds holding
Funds holding: 12 → 11 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$378K |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$294K |
| 3 |
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
|
+$42.9K |
| 4 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$29.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$3.07K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$81.6K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$55.7K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.15K |
| 4 |
SIS
Sound Income Strategies
Ft Lauderdale,
Florida
|
-$36 |
| 5 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$8 |
CNSP Hedge Fund Activity: Q2 2026 in Review
11 of the 8,324 institutional investors tracked by Wall St. Rank reported a position in CNS Pharmaceuticals (CNSP) for Q2 2026, worth a combined $1.34M — up 284% from $349K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CNSP and 4 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.
The largest buyer was Ikarian Capital, adding an estimated $378K. The largest seller was Stonepine Capital Management, cutting an estimated $81.6K.
- 11 institutional investors held CNS Pharmaceuticals (CNSP) as of Q2 2026, down from 12 in Q1 2026.
- Funds reported $1.34M of CNS Pharmaceuticals stock for Q2 2026, up 284% quarter-over-quarter.
- 4 funds opened new CNS Pharmaceuticals positions in Q2 2026 and 5 closed out, a net change of -1 holder.
- The largest CNS Pharmaceuticals buyer in Q2 2026 was Ikarian Capital, an estimated $378K added.
- The largest CNS Pharmaceuticals seller in Q2 2026 was Stonepine Capital Management, an estimated $81.6K sold.
Based on aggregated 13F filings for Q2 2026.